Marshall Wace North America’s Outlook Therapeutics OTLK Stock Holding History

Marshall Wace North America’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,246	Closed	-$100K	–	1812
2018 Q4	$100K	Sell	1,246 -390	-24%	-$48K	﹤0.01%	1085
2018 Q3	$257K	Hold	1,636	–	–	﹤0.01%	812
2018 Q2	$220K	Hold	1,636	–	–	﹤0.01%	1251
2018 Q1	$233K	Hold	1,636	–	–	﹤0.01%	1310
2017 Q4	$340K	Hold	1,636	–	–	﹤0.01%	1217
2017 Q3	$262K	Hold	1,636	–	–	﹤0.01%	1149
2017 Q2	$262K	Hold	1,636	–	–	﹤0.01%	1180
2017 Q1	$785K	Buy	+1,636	New	+$813K	0.01%	739

Other funds holding OTLK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PWMG

Prestige Wealth Management Group Flemington, New Jersey $509M AUM 15.69% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Marshall Wace North America's OTLK Position: Q1 2019 in Review

Marshall Wace North America sold out of Outlook Therapeutics (OTLK) in Q1 2019, closing a stake of 1,246 shares — an estimated $100K sold.

Marshall Wace North America first reported a position in OTLK in Q1 2017 and held it in 8 quarters. The position peaked at $785K in Q1 2017. 14 funds tracked by Wall St. Rank hold OTLK as of Q1 2019.

Marshall Wace North America reported no remaining Outlook Therapeutics position as of Q1 2019 after selling out during the quarter.
Marshall Wace North America sold 1,246 Outlook Therapeutics shares in Q1 2019, an estimated $100K.
Marshall Wace North America first reported a position in Outlook Therapeutics in Q1 2017 and held it in 8 quarters.
Marshall Wace North America's Outlook Therapeutics position peaked at $785K in Q1 2017.
14 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.